vs

Side-by-side financial comparison of BED BATH & BEYOND, INC. (BBBY) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $247.8M, roughly 1.3× BED BATH & BEYOND, INC.). BED BATH & BEYOND, INC. runs the higher net margin — -6.6% vs -18.2%, a 11.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 6.9%). BED BATH & BEYOND, INC. produced more free cash flow last quarter ($-12.8M vs $-133.8M).

Bed Bath & Beyond was an American big-box retail chain specializing in housewares, furniture, and specialty items. Headquartered in Union, New Jersey, the chain operated stores in the United States and Canada, and was once counted among the Fortune 500 and the Forbes Global 2000. The chain filed for Chapter 11 bankruptcy in April 2023 and liquidated all of its remaining stores, with the last closing on July 30, 2023. Following the retail chain's liquidation, its name was adopted by online ret...

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

BBBY vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.3× larger
MDGL
$321.1M
$247.8M
BBBY
Growing faster (revenue YoY)
MDGL
MDGL
+203.9% gap
MDGL
210.8%
6.9%
BBBY
Higher net margin
BBBY
BBBY
11.6% more per $
BBBY
-6.6%
-18.2%
MDGL
More free cash flow
BBBY
BBBY
$121.0M more FCF
BBBY
$-12.8M
$-133.8M
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BBBY
BBBY
MDGL
MDGL
Revenue
$247.8M
$321.1M
Net Profit
$-16.4M
$-58.6M
Gross Margin
23.9%
Operating Margin
68.8%
-18.6%
Net Margin
-6.6%
-18.2%
Revenue YoY
6.9%
210.8%
Net Profit YoY
58.9%
1.4%
EPS (diluted)
$-0.24
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBBY
BBBY
MDGL
MDGL
Q1 26
$247.8M
Q4 25
$273.4M
$321.1M
Q3 25
$257.2M
$287.3M
Q2 25
$282.3M
$212.8M
Q1 25
$231.7M
$137.3M
Q4 24
$303.2M
$103.3M
Q3 24
$311.4M
$62.2M
Q2 24
$398.1M
Net Profit
BBBY
BBBY
MDGL
MDGL
Q1 26
$-16.4M
Q4 25
$-20.9M
$-58.6M
Q3 25
$-4.5M
$-114.2M
Q2 25
$-19.3M
$-42.3M
Q1 25
$-39.9M
$-73.2M
Q4 24
$-81.3M
$-59.4M
Q3 24
$-61.0M
$-107.0M
Q2 24
$-42.6M
Gross Margin
BBBY
BBBY
MDGL
MDGL
Q1 26
23.9%
Q4 25
24.6%
Q3 25
25.3%
Q2 25
23.7%
Q1 25
25.1%
96.7%
Q4 24
23.0%
Q3 24
21.2%
Q2 24
20.1%
Operating Margin
BBBY
BBBY
MDGL
MDGL
Q1 26
68.8%
Q4 25
-4.8%
-18.6%
Q3 25
-4.8%
-39.7%
Q2 25
-4.4%
-22.2%
Q1 25
-10.0%
-57.8%
Q4 24
-11.3%
-64.8%
Q3 24
-14.5%
-187.1%
Q2 24
-11.8%
Net Margin
BBBY
BBBY
MDGL
MDGL
Q1 26
-6.6%
Q4 25
-7.6%
-18.2%
Q3 25
-1.8%
-39.8%
Q2 25
-6.8%
-19.9%
Q1 25
-17.2%
-53.4%
Q4 24
-26.8%
-57.5%
Q3 24
-19.6%
-172.0%
Q2 24
-10.7%
EPS (diluted)
BBBY
BBBY
MDGL
MDGL
Q1 26
$-0.24
Q4 25
$-0.26
$-2.55
Q3 25
$-0.07
$-5.08
Q2 25
$-0.34
$-1.90
Q1 25
$-0.74
$-3.32
Q4 24
$-1.68
$-2.50
Q3 24
$-1.33
$-4.92
Q2 24
$-0.93

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBBY
BBBY
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$135.8M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$202.5M
$602.7M
Total Assets
$404.5M
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBBY
BBBY
MDGL
MDGL
Q1 26
$135.8M
Q4 25
$175.3M
$198.7M
Q3 25
$167.4M
$295.7M
Q2 25
$120.6M
$186.2M
Q1 25
$114.6M
$183.6M
Q4 24
$159.2M
$100.0M
Q3 24
$140.4M
$232.7M
Q2 24
$186.2M
Total Debt
BBBY
BBBY
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
BBBY
BBBY
MDGL
MDGL
Q1 26
$202.5M
Q4 25
$217.6M
$602.7M
Q3 25
$202.6M
$625.7M
Q2 25
$130.9M
$696.0M
Q1 25
$143.4M
$710.6M
Q4 24
$162.7M
$754.4M
Q3 24
$196.2M
$777.2M
Q2 24
$250.4M
Total Assets
BBBY
BBBY
MDGL
MDGL
Q1 26
$404.5M
Q4 25
$425.5M
$1.3B
Q3 25
$414.4M
$1.4B
Q2 25
$358.1M
$1.0B
Q1 25
$363.7M
$996.6M
Q4 24
$402.0M
$1.0B
Q3 24
$428.3M
$1.1B
Q2 24
$496.8M
Debt / Equity
BBBY
BBBY
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBBY
BBBY
MDGL
MDGL
Operating Cash FlowLast quarter
$-11.8M
$-133.5M
Free Cash FlowOCF − Capex
$-12.8M
$-133.8M
FCF MarginFCF / Revenue
-5.2%
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-24.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBBY
BBBY
MDGL
MDGL
Q1 26
$-11.8M
Q4 25
$-6.5M
$-133.5M
Q3 25
$-15.1M
$79.8M
Q2 25
$15.8M
$-47.1M
Q1 25
$-50.9M
$-88.9M
Q4 24
$-21.7M
$-104.5M
Q3 24
$-42.1M
$-67.0M
Q2 24
$-75.9M
Free Cash Flow
BBBY
BBBY
MDGL
MDGL
Q1 26
$-12.8M
Q4 25
$-8.6M
$-133.8M
Q3 25
$-17.4M
$79.0M
Q2 25
$14.0M
Q1 25
$-52.1M
Q4 24
$-24.7M
$-104.7M
Q3 24
$-45.5M
$-67.8M
Q2 24
$-80.4M
FCF Margin
BBBY
BBBY
MDGL
MDGL
Q1 26
-5.2%
Q4 25
-3.2%
-41.7%
Q3 25
-6.8%
27.5%
Q2 25
5.0%
Q1 25
-22.5%
Q4 24
-8.1%
-101.3%
Q3 24
-14.6%
-109.0%
Q2 24
-20.2%
Capex Intensity
BBBY
BBBY
MDGL
MDGL
Q1 26
Q4 25
0.8%
0.1%
Q3 25
0.9%
0.3%
Q2 25
0.6%
0.0%
Q1 25
0.5%
0.0%
Q4 24
1.0%
0.2%
Q3 24
1.1%
1.3%
Q2 24
1.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBBY
BBBY

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons